The global assessment of OCD

Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I

“…A common pitfall in treatment planning is not comprehensively assessing the full clinical presentation and then missing opportunities to design the best treatment plan. Co-morbid mood (more than 60%) and anxiety (more than 75%) diagnoses are extremely common in young people with obsessive-compulsive disorders (OCD) (Pampaloni et al, 2022). These co-morbidities may require careful additional consideration, as they will undoubtedly influence the choice and sequencing of pharmacological interventions for OCD (Lochner et al, 2014).…”

Bridging the gap in the digital age: A commentary on Machado-Sousa et al.’s review and meta-analysis of internet-based CBT for obsessive–compulsive disorder.

“…As noted earlier, OCD is a debilitating illness, with a significant proportion of cases classified in the severe range. 60%-90% of individuals with OCD have at least one other psychiatric comorbidity, with approximately 25% reporting current suicidal ideation and 14% endorsing a history of suicide attempts (Pampaloni et al, 2022). Paired with the aforementioned challenges with accessing treatment, let alone those that are evidence-based, the importance and urgency of ensuring the availability of high-quality care for OCD cannot be overstated.…”

“…In spite of the extant empirical support for CBT, the majority of individuals with anxiety disorders do not have access to treatment, and even among those who are engaged in care, it is often not evidence-based. Obsessive–compulsive disorder (OCD) is a particularly debilitating illness, associated with significant functional impairments, high psychiatric comorbidity, and negative impacts on health-related quality of living (Pampaloni et al, 2022). Although CBT, especially exposure with response prevention (ERP), is also well-established as a first-line treatment for OCD (Katzman et al, 2014), it remains substantially under-recognized and under-treated.…”

The Efficacy of Transcranial Magnetic Stimulation in the Treatment of Obsessive-Compulsive Disorder: An Umbrella Review of Meta-Analyses

“…Obsessive-compulsive disorder (OCD) is a prevalent mental illness, affecting approximately 2%–3% of the population. It typically manifests as a chronic condition and often exists with comorbidities, responds partially to treatment, leading to significant impairment 1 , 2 . A large network meta-analysis evaluating the efficacies of psychotherapeutic interventions and pharmacotherapies in OCD has revealed that the serotonergic medications, including selective serotonin reuptake inhibitors and clomipramine, exhibit similar efficacy, while the combination of pharmacological and psychotherapeutic interventions are more effective than individual treatment modalities 3 .…”

“…It typically manifests as a chronic condition and often exists with comorbidities, responds partially to treatment, leading to significant impairment. 1,2 A large network meta-analysis evaluating the efficacies of psychotherapeutic interventions and pharmacotherapies in OCD has revealed that the serotonergic medications, including selective serotonin reuptake inhibitors and clomipramine, exhibit similar efficacy, while the combination of pharmacological and psychotherapeutic interventions are more effective than individual treatment modalities. 3 After the initiation of treatment with serotonergic medications, significant clinical improvements can be observed (in comparison to placebo) within the initial 2 weeks.…”